Finance

Beta
Lists
LAB:NASDAQ
Standard Biotools Inc
$0.89
+10.33%
(+0.083) 1D
$0.87
-1.83% (-0.016)
After hours
Closed: Jun 9, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LAB...
Open
$0.81
High
$0.91
Low
$0.79
Mkt. cap
313.54M
Avg. vol.
2.96M
Volume
8.34M
52-wk high
$1.72
52-wk low
$0.79
Beta
1.39
Shares outstanding
390.37M
No. of employees
387
Open
$0.81
High
$0.91
Low
$0.79
Mkt. cap
313.54M
Avg. vol.
2.96M
Volume
8.34M
52-wk high
$1.72
52-wk low
$0.79
Beta
1.39
Shares outstanding
390.37M
No. of employees
387
Analyst outlook
Analyst Ratings
Based on 1 analyst giving stock ratings to LAB in the past 3 months
Hold
Buy
0
Hold
1
Sell
0
12 month forecast
Based on 1 Wall Street analyst offering 12 month price targets for LAB in the last 3 months.
Highest
Current $0.89
$1.35 (+52.34%)
Average
$1.35 (+52.34%)
Lowest
$1.35 (+52.34%)
News stories
From sources across the web
Profile
Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits, and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications. Standard BioTools sells products to academic research institutions; translational research and medical centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology and plant and animal research companies; and contract research organizations. Wikipedia
About Standard Biotools Inc
CEO-
Employees387
Founded1999
HeadquartersBoston, Massachusetts, United States
SectorHealth care
Websitestandardbio.com
Last report
May 5, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.02 / -$0.02
+15.50%beat
Revenue / Est. (USD)
21.15M / 19.53M
+8.26%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
21.76M
19.55M
23.80M
21.15M
Cost of goods sold
11.13M
10.07M
12.41M
11.79M
Cost of revenue
11.13M
10.07M
12.41M
11.79M
Research and development expenses
6.22M
6.36M
7.97M
162.00K
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
28.10M
26.60M
25.34M
18.61M
Operating expense
34.33M
32.95M
33.31M
18.77M
Total operating expenses
45.46M
43.02M
45.72M
30.56M
Operating income
-23.70M
-23.47M
-21.92M
-9.42M
Other non operating income
4.96M
-2.09M
4.96M
-2.14M
EBT including unusual items
-18.28M
-32.90M
-22.03M
-14.62M
EBT excluding unusual items
-16.28M
-23.43M
-15.31M
-8.04M
Income tax expense
-609.00K
-1.22M
-35.93M
11.00K
Effective tax rate
3.33%
3.70%
163.10%
-0.08%
Other operating expenses
-
-
-
-
Net income
-33.46M
-34.69M
19.28M
127.07M
Net profit margin
-153.75%
-177.41%
81.04%
600.91%
Earnings per share
-0.04
-0.04
0.07
-0.02
Interest and investment income
2.46M
2.14M
1.66M
3.51M
Interest expense
-9.00K
-10.00K
-5.00K
-
Net interest expenses
2.45M
2.13M
1.66M
3.51M
Depreciation and amortization charges
-
-
-
-
EBITDA
-19.70M
-21.87M
-16.64M
-8.01M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer